Indivior raised 2026 net revenue guidance to $1.295 bln-$1.365 bln from $1.215 bln-$1.285 bln
Company now expects 2026 SUBLOCADE net revenue of $1.01 bln-$1.05 bln, up from $950 mln-$990 mln
Indivior sees 2026 adjusted EBITDA of $700 mln-$740 mln, up from $620 mln-$660 mln
Overview
U.S. opioid treatment maker's Q2 revenue rose 14%, beating analyst expectations
Adjusted EPS for Q2 beat consensus
Company repurchased $175 mln in shares during Q2
Result drivers and key details
SUBLOCADE growth - Co said Q2 revenue growth was driven by a 21% year-over-year rise in SUBLOCADE net revenue, with U.S. SUBLOCADE revenue up 22% on 18% higher dispense unit volume and record new patient starts
Lower operating expenses - Co reported a 25% year-over-year decrease in GAAP operating expenses and a 33% decrease in non-GAAP operating expenses in Q2
Favorable pricing and adjustments - Co said net revenue benefited from more favorable price/mix and gross-to-net adjustments
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Indivior Pharmaceuticals Inc is $49.00, about 22.5% above its July 31 closing price of $40.01
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago
INDV•
